vs
盖茨工业（GTES）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
盖茨工业的季度营收约是Revvity的1.1倍（$856.2M vs $772.1M），Revvity净利率更高（12.7% vs 6.0%，领先6.7%），Revvity同比增速更快（5.9% vs 3.2%），盖茨工业自由现金流更多（$251.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -0.4%）
盖茨工业总部位于美国科罗拉多州丹佛市，是动力传动带及流体动力产品的专业制造商，产品广泛应用于各类工业和汽车领域。公司员工规模超1.5万人，在美洲、欧洲、亚洲、澳洲及中东均设有销售和生产基地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GTES vs RVTY — 直观对比
营收规模更大
GTES
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出2.6%
3.2%
净利率更高
RVTY
高出6.7%
6.0%
自由现金流更多
GTES
多$89.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $856.2M | $772.1M |
| 净利润 | $51.3M | $98.4M |
| 毛利率 | 38.0% | — |
| 营业利润率 | 12.8% | 14.5% |
| 净利率 | 6.0% | 12.7% |
| 营收同比 | 3.2% | 5.9% |
| 净利润同比 | 40.2% | 3.9% |
| 每股收益（稀释后） | $0.19 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTESRVTY
| Q4 25 | $856.2M | $772.1M | ||
| Q3 25 | $855.7M | $698.9M | ||
| Q2 25 | $883.7M | $720.3M | ||
| Q1 25 | $847.6M | $664.8M | ||
| Q4 24 | $829.4M | $729.4M | ||
| Q3 24 | $830.7M | $684.0M | ||
| Q2 24 | $885.5M | $691.7M | ||
| Q1 24 | $862.6M | $649.9M |
净利润GTESRVTY
| Q4 25 | $51.3M | $98.4M | ||
| Q3 25 | $81.6M | $46.7M | ||
| Q2 25 | $56.5M | $53.9M | ||
| Q1 25 | $62.0M | $42.2M | ||
| Q4 24 | $36.6M | $94.6M | ||
| Q3 24 | $47.6M | $94.4M | ||
| Q2 24 | $70.7M | $55.4M | ||
| Q1 24 | $40.0M | $26.0M |
毛利率GTESRVTY
| Q4 25 | 38.0% | — | ||
| Q3 25 | 39.9% | 53.6% | ||
| Q2 25 | 40.8% | 54.5% | ||
| Q1 25 | 40.7% | 56.5% | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 40.4% | 56.3% | ||
| Q2 24 | 40.4% | 55.7% | ||
| Q1 24 | 38.3% | 54.6% |
营业利润率GTESRVTY
| Q4 25 | 12.8% | 14.5% | ||
| Q3 25 | 13.5% | 11.7% | ||
| Q2 25 | 13.1% | 12.6% | ||
| Q1 25 | 14.7% | 10.9% | ||
| Q4 24 | 13.6% | 16.3% | ||
| Q3 24 | 13.6% | 14.3% | ||
| Q2 24 | 15.4% | 12.4% | ||
| Q1 24 | 13.5% | 6.8% |
净利率GTESRVTY
| Q4 25 | 6.0% | 12.7% | ||
| Q3 25 | 9.5% | 6.7% | ||
| Q2 25 | 6.4% | 7.5% | ||
| Q1 25 | 7.3% | 6.4% | ||
| Q4 24 | 4.4% | 13.0% | ||
| Q3 24 | 5.7% | 13.8% | ||
| Q2 24 | 8.0% | 8.0% | ||
| Q1 24 | 4.6% | 4.0% |
每股收益（稀释后）GTESRVTY
| Q4 25 | $0.19 | $0.86 | ||
| Q3 25 | $0.31 | $0.40 | ||
| Q2 25 | $0.22 | $0.46 | ||
| Q1 25 | $0.24 | $0.35 | ||
| Q4 24 | $0.15 | $0.77 | ||
| Q3 24 | $0.18 | $0.77 | ||
| Q2 24 | $0.26 | $0.45 | ||
| Q1 24 | $0.15 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $812.1M | $919.9M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $3.3B | $7.3B |
| 总资产 | $7.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.67× | — |
8季度趋势，按日历期对齐
现金及短期投资GTESRVTY
| Q4 25 | $812.1M | $919.9M | ||
| Q3 25 | $689.4M | $931.4M | ||
| Q2 25 | $719.7M | $991.8M | ||
| Q1 25 | $640.2M | $1.1B | ||
| Q4 24 | $682.0M | $1.2B | ||
| Q3 24 | $574.4M | $1.2B | ||
| Q2 24 | $579.7M | $2.0B | ||
| Q1 24 | $522.2M | $1.7B |
总债务GTESRVTY
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $2.3B | — |
股东权益GTESRVTY
| Q4 25 | $3.3B | $7.3B | ||
| Q3 25 | $3.4B | $7.4B | ||
| Q2 25 | $3.3B | $7.6B | ||
| Q1 25 | $3.1B | $7.6B | ||
| Q4 24 | $3.0B | $7.7B | ||
| Q3 24 | $3.1B | $7.9B | ||
| Q2 24 | $3.2B | $7.9B | ||
| Q1 24 | $3.2B | $7.8B |
总资产GTESRVTY
| Q4 25 | $7.2B | $12.2B | ||
| Q3 25 | $7.1B | $12.1B | ||
| Q2 25 | $7.2B | $12.4B | ||
| Q1 25 | $6.9B | $12.4B | ||
| Q4 24 | $6.8B | $12.4B | ||
| Q3 24 | $7.1B | $12.8B | ||
| Q2 24 | $7.0B | $13.4B | ||
| Q1 24 | $7.0B | $13.4B |
负债/权益比GTESRVTY
| Q4 25 | 0.67× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.73× | — | ||
| Q1 24 | 0.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $269.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $251.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 29.3% | 21.0% |
| 资本支出强度资本支出/营收 | 2.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 5.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $404.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GTESRVTY
| Q4 25 | $269.8M | $182.0M | ||
| Q3 25 | $98.0M | $138.5M | ||
| Q2 25 | $103.0M | $134.3M | ||
| Q1 25 | $7.3M | $128.2M | ||
| Q4 24 | $190.9M | $174.2M | ||
| Q3 24 | $115.9M | $147.9M | ||
| Q2 24 | $93.8M | $158.6M | ||
| Q1 24 | $-21.0M | $147.6M |
自由现金流GTESRVTY
| Q4 25 | $251.0M | $161.8M | ||
| Q3 25 | $80.5M | $120.0M | ||
| Q2 25 | $83.6M | $115.5M | ||
| Q1 25 | $-10.2M | $112.2M | ||
| Q4 24 | $167.6M | $149.8M | ||
| Q3 24 | $94.0M | $125.6M | ||
| Q2 24 | $71.9M | $136.6M | ||
| Q1 24 | $-37.0M | $129.7M |
自由现金流率GTESRVTY
| Q4 25 | 29.3% | 21.0% | ||
| Q3 25 | 9.4% | 17.2% | ||
| Q2 25 | 9.5% | 16.0% | ||
| Q1 25 | -1.2% | 16.9% | ||
| Q4 24 | 20.2% | 20.5% | ||
| Q3 24 | 11.3% | 18.4% | ||
| Q2 24 | 8.1% | 19.7% | ||
| Q1 24 | -4.3% | 20.0% |
资本支出强度GTESRVTY
| Q4 25 | 2.2% | 2.6% | ||
| Q3 25 | 2.0% | 2.6% | ||
| Q2 25 | 2.2% | 2.6% | ||
| Q1 25 | 2.1% | 2.4% | ||
| Q4 24 | 2.8% | 3.4% | ||
| Q3 24 | 2.6% | 3.3% | ||
| Q2 24 | 2.5% | 3.2% | ||
| Q1 24 | 1.9% | 2.7% |
现金转化率GTESRVTY
| Q4 25 | 5.26× | 1.85× | ||
| Q3 25 | 1.20× | 2.97× | ||
| Q2 25 | 1.82× | 2.49× | ||
| Q1 25 | 0.12× | 3.03× | ||
| Q4 24 | 5.22× | 1.84× | ||
| Q3 24 | 2.43× | 1.57× | ||
| Q2 24 | 1.33× | 2.87× | ||
| Q1 24 | -0.53× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTES
| Power Transmission Segment | $536.5M | 63% |
| Fluid Power Segment | $319.7M | 37% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
